Abingdon Health Plc

LSE ABDX.L

Abingdon Health Plc Capital Expenditure for the year ending June 30, 2024: USD -51.89 K

Abingdon Health Plc Capital Expenditure is USD -51.89 K for the year ending June 30, 2024, a 73.96% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Abingdon Health Plc Capital Expenditure for the year ending June 30, 2023 was USD -199.28 K, a 78.46% change year over year.
Abingdon Health Plc Capital Expenditure for the year ending June 30, 2022 was USD -925.33 K, a 90.77% change year over year.
Abingdon Health Plc Capital Expenditure for the year ending June 30, 2021 was USD -10.03 M, a -390.09% change year over year.
Abingdon Health Plc Capital Expenditure for the year ending June 30, 2020 was USD -2.05 M, a -1,574.94% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

LSE: ABDX.L

Abingdon Health Plc

CEO	Mr. Chris Henry Francis Yates
IPO Date	Dec. 15, 2020
Location	United Kingdom
Headquarters	York Biotech Campus
Employees	84
Sector	Technology
Industries 3D Printing Biotechnology Hardware & Electronics Medical Instruments Mobile Apps Pharmaceuticals Smartphones Telehealth

Description

Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

Key trends

Past 5 years